These data demonstrate that targeting CDK4/6 can reverse acquired resistance to PI3K inhibition and provide further support for targeting the PI3K, CDK4/6, and ER signaling pathways either sequentially or as part of an upfront triple combination strategy in ER+/HER2− breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.